Cargando…

Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model

Recent studies have demonstrated that therapy with (212)Pb-TCMC-trastuzumab resulted in (1) induction of apoptosis, (2) G2/M arrest, and (3) blockage of double-strand DNA damage repair in LS-174T i.p. (intraperitoneal) xenografts. To further understand the molecular basis of the cell killing efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, Kwon J, Milenic, Diane E, Baidoo, Kwamena E, Kim, Young-Seung, Brechbiel, Martin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892796/
https://www.ncbi.nlm.nih.gov/pubmed/24403230
http://dx.doi.org/10.1002/cam4.132
_version_ 1782299583141904384
author Yong, Kwon J
Milenic, Diane E
Baidoo, Kwamena E
Kim, Young-Seung
Brechbiel, Martin W
author_facet Yong, Kwon J
Milenic, Diane E
Baidoo, Kwamena E
Kim, Young-Seung
Brechbiel, Martin W
author_sort Yong, Kwon J
collection PubMed
description Recent studies have demonstrated that therapy with (212)Pb-TCMC-trastuzumab resulted in (1) induction of apoptosis, (2) G2/M arrest, and (3) blockage of double-strand DNA damage repair in LS-174T i.p. (intraperitoneal) xenografts. To further understand the molecular basis of the cell killing efficacy of (212)Pb-TCMC-trastuzumab, gene expression profiling was performed with LS-174T xenografts 24 h after exposure to (212)Pb-TCMC-trastuzumab. DNA damage response genes (84) were screened using a quantitative real-time polymerase chain reaction array (qRT-PCR array). Differentially regulated genes were identified following exposure to (212)Pb-TCMC-trastuzumab. These included genes involved in apoptosis (ABL, GADD45α, GADD45γ, PCBP4, and p73), cell cycle (ATM, DDIT3, GADD45α, GTSE1, MKK6, PCBP4, and SESN1), and damaged DNA binding (DDB) and repair (ATM and BTG2). The stressful growth arrest conditions provoked by (212)Pb-TCMC-trastuzumab were found to induce genes involved in apoptosis and cell cycle arrest in the G2/M phase. The expression of genes involved in DDB and single-strand DNA breaks was also enhanced by (212)Pb-TCMC-trastuzumab while no modulation of genes involved in double-strand break repair was apparent. Furthermore, the p73/GADD45 signaling pathway mediated by p38 kinase signaling may be involved in the cellular response, as evidenced by the enhanced expression of genes and proteins of this pathway. These results further support the previously described cell killing mechanism by (212)Pb-TCMC-trastuzumab in the same LS-174T i.p. xenograft. Insight into these mechanisms could lead to improved strategies for rational application of radioimmunotherapy using α-particle emitters. The apoptotic response and associated gene modulations have not been clearly defined following exposure of cells to α-particle radioimmunotherapy (RIT). Gene expression profiling was performed with LS-174T i.p. (intraperitoneal) xenografts after exposure to (212)Pb-TCMC-trastuzumab. Differentially regulated 22 genes were identified following the stressful growth arrest conditions provoked by (212)Pb-TCMC-trastuzumab, providing an informative approach toward understanding the molecular basis of tumor biology in response to α-particle radiation and leading to improved strategies for RIT using α-particle emitters. This study provides data which is among the first to describe in detail, the cellular response to α-particle irradiation in vivo.
format Online
Article
Text
id pubmed-3892796
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Blackwell Science Inc
record_format MEDLINE/PubMed
spelling pubmed-38927962014-01-22 Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model Yong, Kwon J Milenic, Diane E Baidoo, Kwamena E Kim, Young-Seung Brechbiel, Martin W Cancer Med Cancer Biology Recent studies have demonstrated that therapy with (212)Pb-TCMC-trastuzumab resulted in (1) induction of apoptosis, (2) G2/M arrest, and (3) blockage of double-strand DNA damage repair in LS-174T i.p. (intraperitoneal) xenografts. To further understand the molecular basis of the cell killing efficacy of (212)Pb-TCMC-trastuzumab, gene expression profiling was performed with LS-174T xenografts 24 h after exposure to (212)Pb-TCMC-trastuzumab. DNA damage response genes (84) were screened using a quantitative real-time polymerase chain reaction array (qRT-PCR array). Differentially regulated genes were identified following exposure to (212)Pb-TCMC-trastuzumab. These included genes involved in apoptosis (ABL, GADD45α, GADD45γ, PCBP4, and p73), cell cycle (ATM, DDIT3, GADD45α, GTSE1, MKK6, PCBP4, and SESN1), and damaged DNA binding (DDB) and repair (ATM and BTG2). The stressful growth arrest conditions provoked by (212)Pb-TCMC-trastuzumab were found to induce genes involved in apoptosis and cell cycle arrest in the G2/M phase. The expression of genes involved in DDB and single-strand DNA breaks was also enhanced by (212)Pb-TCMC-trastuzumab while no modulation of genes involved in double-strand break repair was apparent. Furthermore, the p73/GADD45 signaling pathway mediated by p38 kinase signaling may be involved in the cellular response, as evidenced by the enhanced expression of genes and proteins of this pathway. These results further support the previously described cell killing mechanism by (212)Pb-TCMC-trastuzumab in the same LS-174T i.p. xenograft. Insight into these mechanisms could lead to improved strategies for rational application of radioimmunotherapy using α-particle emitters. The apoptotic response and associated gene modulations have not been clearly defined following exposure of cells to α-particle radioimmunotherapy (RIT). Gene expression profiling was performed with LS-174T i.p. (intraperitoneal) xenografts after exposure to (212)Pb-TCMC-trastuzumab. Differentially regulated 22 genes were identified following the stressful growth arrest conditions provoked by (212)Pb-TCMC-trastuzumab, providing an informative approach toward understanding the molecular basis of tumor biology in response to α-particle radiation and leading to improved strategies for RIT using α-particle emitters. This study provides data which is among the first to describe in detail, the cellular response to α-particle irradiation in vivo. Blackwell Science Inc 2013-10 2013-09-19 /pmc/articles/PMC3892796/ /pubmed/24403230 http://dx.doi.org/10.1002/cam4.132 Text en © 2013 Published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Cancer Biology
Yong, Kwon J
Milenic, Diane E
Baidoo, Kwamena E
Kim, Young-Seung
Brechbiel, Martin W
Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
title Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
title_full Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
title_fullStr Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
title_full_unstemmed Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
title_short Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
title_sort gene expression profiling upon (212)pb-tcmc-trastuzumab treatment in the ls-174t i.p. xenograft model
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892796/
https://www.ncbi.nlm.nih.gov/pubmed/24403230
http://dx.doi.org/10.1002/cam4.132
work_keys_str_mv AT yongkwonj geneexpressionprofilingupon212pbtcmctrastuzumabtreatmentinthels174tipxenograftmodel
AT milenicdianee geneexpressionprofilingupon212pbtcmctrastuzumabtreatmentinthels174tipxenograftmodel
AT baidookwamenae geneexpressionprofilingupon212pbtcmctrastuzumabtreatmentinthels174tipxenograftmodel
AT kimyoungseung geneexpressionprofilingupon212pbtcmctrastuzumabtreatmentinthels174tipxenograftmodel
AT brechbielmartinw geneexpressionprofilingupon212pbtcmctrastuzumabtreatmentinthels174tipxenograftmodel